Synthetic Biologics has formed a clinical advisory board to support development of SYN-004, its lead anti-infective product candidate for the prevention of the effects of Clostridium difficile.
The new board is comprised of Mark Wilcox, MD, who will serve as chair; Curtis Donskey, MD; Ciarán Kelly, MD; and Tom Louie, MD. Synthetic Biologics plans to initiate phase Ia and Ib clinical trials to evaluate SYN-004 in the second half of 2014.
"SYN-004 has the potential to have a significant impact on mitigating this urgent public health threat, and I look forward to working with the other advisory board members to help the company move this promising program forward as expeditiously and strategically as possible," said Dr. Wilcox in a news release.
More Articles on Quality:
Despite Guidelines, Antibiotics Prescribed at High Rate for Bronchitis
New Pathogen-Identification Method Leads to Cost Savings: Study
Kaiser South Sacramento Patients Potentially Exposed to Whooping Cough